Overview of Oxaprozin
Oxaprozin, marketed under the NDC code 69238-1120 by Amneal Pharmaceuticals NY LLC, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain, inflammation, and stiffness caused by various conditions such as osteoarthritis and rheumatoid arthritis[5].
Current Market Context
Prescription Drug Price Trends
The pharmaceutical market, particularly in the U.S., has seen significant price increases over recent years. From 2017 to 2022, the average price increase for prescription drugs in the U.S. was 14%, which is substantially higher than the decreases observed in other parts of the world and the OECD countries[4].
For multi-source drugs like Oxaprozin, the price increases tend to be higher in percentage terms but lower in absolute dollar values compared to single-source drugs. For instance, from January 2022 to January 2023, the average price increase for multi-source drugs was 26.0%, translating to a $69 increase per drug, while single-source drugs saw a 7.4% increase, amounting to $958 per drug[2].
Price History and Projections
Historical Price Changes
While specific historical price data for Oxaprozin (NDC: 69238-1120) is not provided, the general trend for NSAIDs and multi-source drugs suggests periodic price adjustments. Given that Oxaprozin is a generic drug, its prices are generally more stable but can still fluctuate based on market conditions and regulatory changes.
Projected Price Changes
Based on the broader trends in the pharmaceutical industry:
-
Short-Term Projections: For 2025, it is likely that Oxaprozin will experience a moderate price increase, aligning with the average annual increases observed for multi-source drugs. A 10-15% increase is plausible, considering the historical data and the ongoing trend of higher price increases for multi-source drugs[2].
-
Long-Term Projections: Over the next few years, the biopharma and biotech industries are expected to see significant growth driven by technological advancements and evolving regulatory landscapes. However, for generic drugs like Oxaprozin, the price growth is likely to be more muted compared to innovative biopharmaceuticals. The compound annual growth rate (CAGR) for the biopharma market is projected to be around 7.56% between 2024 and 2029, but this growth is more relevant to branded and innovative drugs rather than generics[3].
Market Factors Influencing Price
Regulatory Environment
Changes in regulatory frameworks can significantly impact drug prices. For instance, evolving clinical trial designs and precision medicine trends may influence the development and pricing of new drugs, but these changes are less likely to affect the pricing of established generic drugs like Oxaprozin[3].
Global Pricing Comparisons
The U.S. market is known for having higher prescription drug prices compared to other countries. Oxaprozin, being a generic drug, would still be priced higher in the U.S. than in many other countries, but the price differential is less pronounced for generics compared to branded drugs[4].
Market Competition
The presence of multiple manufacturers for Oxaprozin, including Amneal Pharmaceuticals, helps maintain competitive pricing. However, the overall market dynamics, including the number of manufacturers and the demand for the drug, can influence price stability or fluctuations.
Consumer and Payer Impact
Patient Access and Affordability
Price increases, even if moderate, can affect patient access and affordability. For drugs like Oxaprozin, which are often prescribed for chronic conditions, consistent price increases can lead to higher out-of-pocket costs for patients, especially those without comprehensive insurance coverage.
Payer Strategies
Payers, including insurance companies and government programs, may implement various strategies to manage the impact of price increases. These can include formulary changes, copayment adjustments, and negotiation of discounts with manufacturers.
Key Takeaways
- Price Stability: Oxaprozin, as a generic drug, is likely to experience more stable pricing compared to branded or innovative drugs.
- Moderate Increases: Short-term price projections suggest a moderate increase of around 10-15% in 2025.
- Regulatory and Market Factors: Changes in regulatory environments and market competition will continue to influence pricing.
- Global Pricing: U.S. prices for Oxaprozin remain higher than in other countries but are less affected by global pricing trends compared to branded drugs.
FAQs
1. What is Oxaprozin used for?
Oxaprozin is used to treat pain, inflammation, and stiffness caused by conditions such as osteoarthritis and rheumatoid arthritis.
2. Who manufactures Oxaprozin under NDC 69238-1120?
Oxaprozin under NDC 69238-1120 is manufactured by Amneal Pharmaceuticals NY LLC.
3. How do price trends for multi-source drugs compare to single-source drugs?
Multi-source drugs tend to have higher percentage price increases but lower absolute dollar increases compared to single-source drugs.
4. What are the projected price changes for Oxaprozin in 2025?
A moderate price increase of around 10-15% is projected for Oxaprozin in 2025.
5. How do regulatory changes impact the pricing of generic drugs like Oxaprozin?
Regulatory changes are less likely to significantly impact the pricing of established generic drugs like Oxaprozin compared to innovative biopharmaceuticals.
Sources
- FindACode: Amneal Pharmaceuticals NY LLC - List of Drugs - NDC Labeler.
- ASPE: Changes in the List Prices of Prescription Drugs, 2017-2023.
- TFS CRO: 5 Predictions for the Biopharma and Biotech Industries in 2025.
- ASPE: International Market Size and Prices.
- DailyMed: OXAPROZIN tablet.
